Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

SAN FRANCISCO, Nov. 12 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, today announced the expansion of its clinical advisory board. Joining the clinical advisory board's chair, Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, Harvard Medical School, and Senior Physician, Brigham & Women's Hospital in Boston, and Jean-Claude Tardif, M.D., Associate Professor of Medicine, University of Montreal, and Director of Research, Montreal Heart Institute, are Marcelo Di Carli, M.D., Associate Professor of Radiology, and Chief of Nuclear Medicine, Brigham and Women's Hospital; Robert Fenichel, M.D., Ph.D, Former Deputy Division Director, Division of CardioRenal Drug Products, Food and Drug Administration; Peter Libby, M.D., Mallinckrodt Professor of Medicine, and Chief, Cardiovascular Division, Brigham and Women's Hospital; and, Jean-Lucien Rouleau, M.D., Dean, Faculty of Medicine, University of Montreal.

"The addition of these well-respected physicians to VIA's clinical advisory board comes at an important time in our history," said Larry Cohen, Ph.D., president and chief executive officer of VIA. "As we prepare for the release of Phase II clinical trial data in the middle of 2008, our clinical advisory board will provide independent medical, scientific, and regulatory guidance in supporting our efforts to advance VIA-2291 as a treatment of cardiovascular disease."

About VIA-2291

VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversib
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... Barnhardt Manufacturing Company has earned the ... Cotton . The USDA Certified Biobased Product Label verifies ... or exceeds levels set by USDA. Biobased products are ... significant part of agricultural, forestry, or marine ingredients. ... be immediately identified as a USDA certified BioPreferred ...
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/19/2014)... The new , Healthcare and Life ... today on PharmaBoardroom.com for free download , ... the Spanish economy in 2009, and the austerity measures that ... pragmatic in times of trouble. "Despite the crisis, ... European market, and the general conditions to invest are favorable ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Barnhardt Manufacturing Company Earns USDA Certified Biobased Product Certification and Label for Organic Cotton 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3
... a new explanation for differences in the severity of mental illness ... more serious the handicap. The genetic defect is situated on the ... copies of the GDI1 gene that is responsible. The results are ... and are the result of work by the group of Guy ...
... Calif., Dec. 11 Marrone Bio Innovations (MBI) today ... Mr. Chris Hildreth joined MBI as Senior Vice President ... commercial aspects of the company, including sales, marketing, and ... MBI as Vice President of Process Development, and leads ...
... Dendreon Corporation (Nasdaq: DNDN ) announced today that it has ... stock at a price to the public of $24.75 per share. ... purchase up to an additional 2,250,000 shares of common stock to ... on December 15, 2009, subject to customary closing conditions. , J. ...
Cached Biology Technology:Amount of gene surplus determines severity of mental retardation in males 2Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
(Date:9/19/2014)... a species which over thousands of years has adapted to ... substance that makes the cold dangerous for you. , This ... , and the cold provoking substance, called nonylphenol, comes from ... is suspected of being a endocrine disruptor, but when entering ... worm,s ability to protect the cells in its body from ...
(Date:9/18/2014)... Colo., USA A new GSA Bulletin ... the lower Rio Puerco and Chaco Wash in northern ... rings from salt cedar and willow, investigators were able ... or greater. They then combined this data with aerial ... the history of these arroyos. , Arroyos are deep, ...
(Date:9/18/2014)... system that can operate inside the bore of an ... a biomedical research partnership program at Brigham and Women,s ... the robot, in conjunction with real-time MRI images, can ... and less discomforting for the patient. The novel system ... with greater precision. , Developed by a team of ...
Breaking Biology News(10 mins):Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3Tree rings and arroyos 2Tree rings and arroyos 3Tree rings and arroyos 4Tree rings and arroyos 5Tree rings and arroyos 6Tree rings and arroyos 7Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
... 3, 2009 Two scientists whose work has led to ... dystrophy have been chosen to receive the 2009 March of ... Ph.D. and Louis M. Kunkel, Ph.D., will share the 2009 ... genes and proteins that cause muscular dystrophy, a disorder in ...
... 2009 Signal Hill, CA Tom Bowman, ... helps organizations make sustainable transformations, has written a ... programs required to encourage sustainable behaviors and drive ... paper, entitled "A Turning Point in Climate Change ...
... BALTIMOREPediatric experts from Children,s National Medical Center ... at the 2009 Pediatric Academic Societies Annual Meetingthe largest ... Presenters and topics include: ... will present the outcomes of her innovative and successful ...
Cached Biology News:March of Dimes awards $250,000 prize to scientists unraveling the causes of muscular dystrophy 2Children's National experts present at Pediatric Academic Societies' Annual Meeting 2Children's National experts present at Pediatric Academic Societies' Annual Meeting 3
... Duo is suitable for use with a ... solvents through to water and some of ... concentrator capable of removing water and organic ... including tubes, microplates, vials and round bottom ...
... Precision Model 410 is a four-channel general purpose ... small signals from sources which may have a ... channel consists of a high gain/low noise amplifier, ... and an output offset control. A control knob ...
Proliferin (N-14)...
Porcine Aortic Smooth Muscle Cells (PAOSMC) (>500,000 cells)...
Biology Products: